Core Insights - Tarsus Pharmaceuticals reported significant growth in net product sales for XDEMVY, achieving $66.4 million in the fourth quarter and $180.1 million for the full year 2024, marking a substantial increase from previous periods [1][3][5] - The company presented groundbreaking data indicating that XDEMVY is the first pharmacologic treatment to show functional improvements in Meibomian Gland Disease and symptoms in patients with Demodex blepharitis [1][3] - Tarsus is advancing its pipeline with TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention, indicating a commitment to addressing unmet needs in eye care and infectious disease [1][3][16] Financial Performance - For Q4 2024, Tarsus reported net product sales of $66.4 million, a significant increase from $13.1 million in Q4 2023, driven by the dispensing of over 58,500 bottles of XDEMVY [3][5][18] - Full-year 2024 net product sales reached $180.1 million, compared to $14.7 million in 2023, with more than 163,000 bottles dispensed [3][5][18] - The company recognized a gross-to-net discount of approximately 45% in both the fourth quarter and full year 2024 [3] Business Highlights - Tarsus established broad utilization of XDEMVY among over 15,000 Eye Care Professionals (ECPs) and expanded its sales force, contributing to increased prescription volumes [3][5] - A Direct-To-Consumer (DTC) campaign launched in Q4 2024 has shown positive initial patient responses, with plans to expand into network television in 2025 [3][5] - The company is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY by 2027 [7] Research and Development - R&D expenses for Q4 2024 were $16.9 million, up from $13.3 million in the same period in 2023, primarily due to increased milestone expenses and program spending [5][15] - Tarsus plans to initiate a Phase 2 study for TP-04 in the second half of 2025, following positive FDA feedback [3][7] - The company is also advancing TP-05, an investigational oral tablet aimed at preventing Lyme disease transmission [3][16] Management and Leadership - Tarsus strengthened its leadership team with the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer and Katherine H. Goodrich, M.D., to the Board of Directors, enhancing its expertise in eye care [7][16] - The company is focused on expanding its development and regulatory capabilities to support its growth in the eye care sector [7][16]

Company Overview - Tarsus Pharmaceuticals, Inc. focuses on revolutionizing treatment for patients, particularly in eye care, by applying proven science and new technology [2] - The company is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including eye care and infectious disease prevention [2] Product Development - Tarsus has FDA approval for XDEMVY® (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis [2] - The company is developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease [2] Upcoming Events - Tarsus Pharmaceuticals will host a live webcast on February 25, 2025, at 5:00 a.m. PT / 8:00 a.m. ET to report its fourth quarter and full-year 2024 financial results and provide a corporate update [1]

Summary of Tarsus Pharmaceuticals Conference Call Company Overview - **Company**: Tarsus Pharmaceuticals - **Product Launched**: XtEMVI for Demodex blepharitis launched in September 2023 - **Revenue**: Over $113 million for the nine months ended Q3 2023 - **Target Audience**: 15,000 doctors, with 13,000 writing prescriptions, and over 70% of those writing multiple scripts [3][4][5] Key Points and Arguments Product Performance - **XtEMVI Launch**: Initial skepticism about the disease state, but the product is positioned as a category-creating therapy [4] - **Market Potential**: Targeting a patient population of approximately 9 million for ocular rosacea, with no current competition [5][6] - **Lyme Disease Program**: Oral prophylactic treatment showing 98% efficacy in killing ticks before transmission of Lyme disease [6][7] Financial Guidance and Market Dynamics - **Seasonality Impact**: Anticipated growth tempered by seasonality, particularly in Q1 and Q3 due to insurance changes and summer vacations [10][11] - **Refill Expectations**: Currently not seeing significant refill impacts due to the recent launch; refills expected to increase as the product matures [10][12] - **Bottle Guidance**: Guidance for 50,000 to 55,000 bottles for Q4, with potential for higher actuals [14][18] Sales and Marketing Strategy - **Sales Force Expansion**: 50 new sales representatives hired to enhance market penetration [17][19] - **Direct-to-Consumer Campaign**: Early signs of patient engagement from DTC campaigns, but significant impact expected in 3-6 months [22][23] Market Opportunities - **MGD Patients**: Identifying an additional 1.5 to 2 million patients with Meibomian Gland Dysfunction (MGD) who may also have Demodex blepharitis [27][31] - **Ocular Rosacea**: New indication with an estimated 10 to 15 million patients, primarily caused by Demodex mites [58] Financial Position - **Cash Position**: Ended Q3 with $317 million in cash and a $100 million term loan available [61] Other Important Content - **Gross to Net Dynamics**: Anticipated gross to net discount of about 40% in Q3, expected to increase in Q4 and Q1 due to patient dynamics and insurance changes [39][41] - **Medicare Coverage**: Secured coverage from major Medicare payers, expected to provide a tailwind for growth [45] - **Clinical Trials for Ocular Rosacea**: Plans to initiate studies in the second half of 2025, focusing on the unique treatment needs of ocular rosacea patients [49][48] This summary encapsulates the key insights from the Tarsus Pharmaceuticals conference call, highlighting the company's strategic direction, market opportunities, and financial outlook.

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) is experiencing a downtrend with a 9.1% decline over the past four weeks, but it is in oversold territory, suggesting a potential turnaround due to analysts' positive earnings outlook [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 indicating oversold conditions [2] - TARS has an RSI reading of 28.74, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible trend reversal [5] Group 2: Fundamental Indicators - Analysts have raised earnings estimates for TARS by 10.2% over the last 30 days, indicating a strong consensus among sell-side analysts that could lead to price appreciation [6] - TARS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [7]

Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][2][7] Company Updates - In 2024, Tarsus established XDEMVY as one of the most successful eye care launches, achieving consistent quarter-over-quarter revenue growth and broad payer coverage, with over 104,000 bottles delivered and more than $113 million in net product sales during the first nine months of 2024 [3][7] - The company plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] - Tarsus has deployed approximately 50 new sales representatives in Q3 2024, which is expected to positively impact sales in Q4 2024 [7] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [10][14] - Ocular Rosacea affects approximately 15-18 million Americans, with TP-04 representing a potential category-creating therapy for this condition [7][12] - The company anticipates potential European regulatory approval for a preservative-free formulation of XDEMVY in 2027 and is working on regulatory pathways in Japan and China for its products [7][14]

Core Insights - Tarsus Pharmaceuticals is advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, a significant eye disease with no FDA-approved therapy, with plans to initiate a Phase 2 study in the second half of 2025 [1][6][11] Company Updates - Tarsus reported that 2024 was a groundbreaking year with XDEMVY achieving consistent quarter-over-quarter revenue growth, rapid physician adoption, and broad payer coverage, generating over $113 million in net product sales during the first nine months of 2024 [3][6] - The company delivered more than 104,000 bottles of XDEMVY to patients, with over 13,000 Eye Care Professionals prescribing it, and more than 70% of these professionals writing prescriptions for multiple patients [6] - Tarsus plans to enhance its strategic initiatives in 2025, focusing on generating new evidence for XDEMVY and pursuing Ocular Rosacea as a transformative opportunity in eye care [3][6] Product Information - XDEMVY (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis by targeting Demodex mite infestation, with pivotal trials showing significant improvements in key endpoints [9][10] - TP-04 is an investigational formulation of lotilaner aimed at treating Ocular Rosacea, which affects approximately 15-18 million Americans, with a clear regulatory path established based on FDA feedback [6][11] Future Plans - The company is on track for potential European regulatory approval of a preservative-free formulation of XDEMVY in 2027 and anticipates sharing results from a prevalence study in Japan in 2025 [14] - Tarsus is also developing TP-05, an oral systemic formulation of lotilaner, aimed at preventing Lyme disease transmission [12][13]

Core Viewpoint - Tarsus Pharmaceuticals, Inc. (TARS) shows potential for further upside, with a mean price target of $64 indicating a 27% upside from its current price of $50.40, following a 10.4% gain over the past four weeks [1]. Price Target Analysis - The average price target consists of eight estimates ranging from a low of $41 to a high of $84, with a standard deviation of $12.83, indicating variability among analysts [2]. - The lowest estimate suggests an 18.7% decline, while the highest indicates a 66.7% upside, highlighting the range of opinions among analysts [2]. Analyst Sentiment - Analysts exhibit strong agreement on TARS's ability to report better earnings than previously predicted, which supports the expectation of an upside [4]. - A positive trend in earnings estimate revisions has been shown to correlate with stock price movements, reinforcing the potential for TARS's stock to rise [9]. Earnings Estimates - Over the last 30 days, six earnings estimates for TARS have been revised upward, with no negative revisions, leading to a 13.4% increase in the Zacks Consensus Estimate [10]. - TARS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [11]. Conclusion on Price Targets - While the consensus price target may not be a reliable predictor of TARS's price movement, the direction implied by the targets appears to be a useful guide for investors [12].

Shares of Tarsus Pharmaceuticals, Inc. (TARS) have gained 22.4% over the past four weeks to close the last trading session at $44.83, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $63.25 indicates a potential upside of 41.1%.The average comprises eight short-term price targets ranging from a low of $41 to a high of $84, with a standard deviation of $13.65. While the lowest est ...

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 32.22%. A quarter ago, it was expected that this company would post a loss of $0.98 per share when it actually produced a loss of $0.88, delivering a surprise of 10.20%.Over the last four quarters, the company ...

Core Insights - Tarsus Pharmaceuticals has appointed Dr. Katherine H. Goodrich, CMO of Humana Inc., to its Board of Directors, bringing over two decades of experience in innovative healthcare initiatives aimed at improving patient outcomes [1][2] Company Overview - Tarsus Pharmaceuticals focuses on unmet medical needs and aims to revolutionize treatment, particularly in eye care, by applying proven science and new technology [1][5] - The company is advancing its pipeline to address diseases with high unmet needs across various therapeutic categories, including eye care, dermatology, and infectious disease prevention [5] Leadership and Expertise - Dr. Goodrich has a significant background in value-based care, having previously served as CMO of Medicare and currently leading clinical initiatives at Humana [2][3] - Her role at Humana includes overseeing physician engagement, healthcare research, health equity, and social impact initiatives [2] - Dr. Goodrich has also held leadership positions at the Centers for Medicare and Medicaid Services, where she directed quality and value-based purchasing programs [3] Clinical Development - Tarsus is studying three investigational medicines in clinical trials, including XDEMVY, which is FDA approved for treating Demodex blepharitis, and two others targeting Meibomian Gland Disease and Rosacea, as well as an oral tablet for Lyme disease prevention [5]